State Street’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

State Street’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-361,954	Closed	-$525K	–	3878
2018 Q1	$525K	Buy	361,954 +22,954	+7%	+$47.9K	﹤0.01%	3430
2017 Q4	$763K	Buy	339,000 +9,783	+3%	+$24.8K	﹤0.01%	3393
2017 Q3	$1.12M	Buy	329,217 +500	+0.2%	+$1.68K	﹤0.01%	3357
2017 Q2	$1.17M	Buy	328,717 +63,773	+24%	+$210K	﹤0.01%	3304
2017 Q1	$901K	Buy	264,944 +38,000	+17%	+$148K	﹤0.01%	3290
2016 Q4	$1.04M	Buy	226,944 +72,123	+47%	+$298K	﹤0.01%	3268
2016 Q3	$658K	Buy	154,821 +59,845	+63%	+$194K	﹤0.01%	3256
2016 Q2	$226K	Sell	94,976 -1,242	-1%	-$4.49K	﹤0.01%	3498
2016 Q1	$452K	Buy	96,218 +5,000	+5%	+$19.3K	﹤0.01%	3373
2015 Q4	$358K	Buy	91,218 +65,800	+259%	+$303K	﹤0.01%	3397
2015 Q3	$99K	Buy	+25,418	New	+$117K	﹤0.01%	3540

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

State Street's AST Position: Q2 2018 in Review

State Street sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 361,954 shares — an estimated $525K sold.

State Street first reported a position in AST in Q3 2015 and held it in 11 quarters. The position peaked at $1.17M in Q2 2017. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

State Street reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
State Street sold 361,954 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $525K.
State Street first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 11 quarters.
State Street's Asterias Biotherapeutics Inc. Series A position peaked at $1.17M in Q2 2017.
62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on State Street's 13F filing for Q2 2018, filed 14 Aug 2018.